Steinberg Ryan L, Johnson Brett A, Cadeddu Jeffrey A
Department of Urology, University of Texas Southwestern, Dallas, TX.
Department of Urology, University of Texas Southwestern, Dallas, TX.
Urology. 2019 Apr;126:237. doi: 10.1016/j.urology.2019.01.017. Epub 2019 Jan 24.
Tissue retraction during minimally-invasive urologic surgery currently is achieved by either gravity via patient positioning or placement of additional ports for robotic arms or bedside assistant instrumentation. A novel magnetic retractor system (Levita Magnetic Surgical System, San Mateo, CA) was recently approved by the Food and Drug Administration for use in minimally invasive surgery.
To evaluate the safety and efficacy of magnetic-assisted robotic surgery (MARS) to perform a reduced-port radical prostatectomy (RP).
Sixteen patients underwent a MARS reduced-port RP in the treatment of prostatic adenocarcinoma at a single institution from June 2018 to September 2018 utilizing the magnetic retraction device in lieu of the 4th robotic arm for tissue retraction. All surgical procedures were completed using the da Vinci surgical system (Intuitive Surgical Inc., Sunnyvale, CA). The magnetic retractor was used to manipulate and retract the colon, peritoneum, seminal vesicles, prostatic capsule during neurovascular bundle dissection, and bladder during lymphadenectomy.
All cases were successfully completed without placement of a 4th robotic arm or an additional assistant port. The magnetic retractor subjectively provided comparable retraction and exposure to these tools. No intraoperative or immediate postoperative complications were noted. Mean operative time was 236 ± 23 minutes and mean blood loss was 265 ± 88 mL. All patients were discharged to home by postoperative day 2.
Magnetic-assisted reduced-port robotic prostatectomy is a novel technique that appears to be both safe and effective. Use of the magnetic system avoids the need for a 4th robotic arm, potentially minimizing the morbidity of surgery and improving cosmesis. Further, none of the fundamental steps of the procedure were changed or compromised. Outcomes analysis in larger cohorts and cost analysis is warranted.
目前,微创泌尿外科手术中的组织牵拉可通过患者体位利用重力实现,或通过为机械臂或床边辅助器械放置额外端口来完成。一种新型磁牵开器系统(Levita磁外科系统,加利福尼亚州圣马特奥)最近获得美国食品药品监督管理局批准,可用于微创手术。
评估磁辅助机器人手术(MARS)用于实施减少端口的根治性前列腺切除术(RP)的安全性和有效性。
2018年6月至2018年9月期间,16例患者在单一机构接受了MARS减少端口RP,以治疗前列腺腺癌,使用磁牵开装置代替第四机械臂进行组织牵拉。所有手术均使用达芬奇手术系统(直观外科公司,加利福尼亚州森尼韦尔)完成。在神经血管束解剖过程中,磁牵开器用于操作和牵拉结肠、腹膜、精囊、前列腺包膜,在淋巴结清扫过程中用于牵拉膀胱。
所有病例均成功完成,未放置第四机械臂或额外的辅助端口。磁牵开器在主观上提供了与这些工具相当的牵拉和暴露效果。未观察到术中或术后即刻并发症。平均手术时间为236±23分钟,平均失血量为265±88毫升。所有患者均在术后第2天出院回家。
磁辅助减少端口机器人前列腺切除术是一种新技术,似乎既安全又有效。使用磁系统避免了对第四机械臂的需求,可能将手术发病率降至最低并改善美观。此外,该手术的所有基本步骤均未改变或受到影响。有必要对更大队列进行结果分析和成本分析。